ServiziMenu principaleHome
You are here: Home > Events > Future Events > Molecular Diagnostics and Genomics in Breast Cancer

Molecular Diagnostics and Genomics in Breast Cancer

01.03.2021  -  05.03.2021



Due to the ongoing Coronavirus (COVID-19) crisis, SPCC has made the difficult decision, in agreement with the chairs and sponsors, to commute the event into a virtual meeting.
We deeply regret having to take this decision but we feel that in the current climate this was the only decision possible.
The new dates will be 1-5 March 2021.

The event attendance will be free of charge, but registration is required on the SPCC website.


M.S. Aapro, CH  - J. Gligorov, FR


The main common feature of cancer cells is their ability to escape to homeostatic regulation mechanisms of living. In a sense giving them immortality, causing in the absence of treatment the death of the organism, which is their origin. The exponential knowledge of the biology of cancer and the phenomenal capacity of synthesis of new treatments and diagnostic tools have opened up the prospect of a precision medicine in oncology that requires regular and frequent updating of our knowledge.
This knowledge concerns both the intrinsic prognosis of the disease, as the prediction value of therapeutic approaches that in fact becomes increasingly “personalized”. This course aims to take stock of current and future tools that help us optimize the care of patients with breast cancer.

Learning Objectives

  • Improve breast cancer patients care: value and clinical utility of prediction of CT benefit for early stage breast cancer patients
  • Practicing through case discussions


 Under the auspices of




Matti Aapro, Clinique de Genolier, Breast Center, Genolier, CH
Fabrice André, Institut Gustave Roussy, Dept. of Medical Oncology, Villejuif, FR
Anna Batistatou, University of Ioannina, Faculty of Medicine, Ioannina, GR
Francesco Cognetti, Istituto Nazionale Tumori Regina Elena, Dipartimento di Oncologia Medica, Roma, IT
Joseph Gligorov, University Cancer Institute APHP.6 Sorbonne University, Breast Cancer Expert Center, Paris, FR
Susan Knox, Europa Donna - The European Breast Cancer Coalition, Milan, IT
Christos Markopoulos, Athens, GR
Riccardo Masetti, Università Cattolica di Roma, Oncology Dpt., Roma, IT
Belinda Nedjai, Queen Mary University of London, Wolfson Institute of Preventive Medicine - Centre for Cancer Prevention, London, GB
Frederique Penault Llorca, Centre Jean Perrin, Anatomopathology Dpt., Clermont-ferrand Cedex, FR
Giancarlo Pruneri, Fondazione IRCCS - Istituto Nazionale dei Tumori, Pathology Dpt., Milano, IT
Pascale Pujol, Centre Hospitalier Universitaire de Montpellier, Genetics Department, Montpellier Cedex5, FR
Elzbieta Senkus, Medical University of Gdansk, Dept. of Oncology and Radiotherapy, Gdansk, PL
Zsuzsanna Varga, University Hospital Zurich, Pathology Dept., Zurich, CH
Mark Verrill, Northern Centre for Cancer Care, Freeman Hospital, Medical Oncology Dept., Newcastle upon Tyne, GB

General information


Sharing Progress in Cancer Care
Piazza Indipendenza, 2
6500 Bellinzona – Switzerland

Luis Carvalho
Luis.carvalho@spcc.net  - Tel: +41 91 820 09 58

CME Accreditation and Certificates

Participants will be entitled to receive a certificate of attendance at the close of the event by completing the on-line evaluation questionnaire.

Application for CME recognition has been submitted to the Accreditation Council of Oncology in Europe (ACOE).

ACOE credits are recognised by the American Medical Association towards the Physician’s Recognition Award (PRA).

Information on the status of the applications can be obtained from the organising secretariat.


Sharing Progress in Cancer Care wishes to extend its appreciation to Daiichi SankyoExact Sciences and Pfizer for having granted their participation and support to the Course.

Terms and Conditions

The event attendance will be free of charge, but registration is required on the SPCC website.



01 March

16:00Welcome and introduction
Chair: Matti Aapro, CH - Joseph Gligorov, FR
16:05Optimize patient management in breast cancer: guiding adjuvant treatment decisions
16:20Clinical utility of multigene assays in early breast cancer
 16:20Predictive tests
 16:30Prognostic tests
16:40Who to test with multigene assay: treatment algorithms – specific patient profiles (lobular; premenopausal CT decisions)
 16:40Clinical perspective
 16:50Next Generation Sequencing
17:00Discussion and Q&A

02 March

16:00Welcome and introduction
16:05Roundtable: Evidence based assessment of diagnostic tests: criteria for a health technology assessment – why outcomes of HTA decisions can be different…?
 16:05The French rationale
 16:15Why NICE accepted?
 16:25Why German authorities accepted?
16:35The essential pathology testing needed for breast cancer, quality control
Anna Batistatou, GR
16:50What TESTS to ask for and what clinical implications in "TRIPLE NEGATIVE" BrCa”
Nadia Harbeck, DE
17:05The patient’s perspective: patient preferences, patient journey
Susan Knox, IT
17:25Discussion and Q&A

03 March

16:00Welcome and introduction
16:05Group session: Patient Case discussion on multigene assays in early breast cancer: who to test and how to deal with the results?
 16:05Goup 1
 16:05Group 2
17:05Panellists case discussion summary and Q&A

04 March

16:00Advanced breast cancer (PART1)
16:05DNA Methylation
16:25NGS impact or not in breast cancer
16:45Alpelisib what to test
 16:45Clinical positioning
 17:00What to test
17:15Discussion and Q&A

05 March

16:00Advanced breast cancer (PART2)
16:00Welcome and intruduction
16:05Parp inhibitors what to test
 16:20Clinical implication
16:35Immunotherapy: what to test
 16:50Clinical implication
17:05HER-2 alterations not defined as ASCO CAP HER-2 positivity
 17:20Clinical implication
Joseph Gligorov, FR
17:35Discussion and Q&A